CClinicalTrials.gg
Sign In
RecruitingNCT07589608Updated Sep 22, 2026

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

A Phase 2 interventional study of Macupatide and Eloralintide in Overweight and Obesity, sponsored by Eli Lilly and Company. Recruiting at 40 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

02

Conditions studied

  • Overweight
  • Obesity
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion criteria

Exclusion Criteria:

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

  • Have type 1 diabetes or type 2 diabetes
  • Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
  • Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
  • Have a history of acute or chronic pancreatitis
  • All concomitant medications should be at a stable dose for at least 3 months prior to screening
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Macupatide Dose 1

    Participants will receive macupatide subcutaneously (SC)

    Drug: Macupatide

  • Experimental
    Eloralintide Dose 1

    Participants will receive eloralintide SC

    Drug: Eloralintide

  • Experimental
    Macupatide Dose 1 + Eloralintide Dose 1

    Participants will receive macupatide SC and eloralintide SC

    Drug: Macupatide · Drug: Eloralintide

  • Experimental
    Eloralintide Dose 2

    Participants will receive eloralintide SC

    Drug: Eloralintide

  • Experimental
    Macupatide Dose 1 + Eloralintide Dose 2

    Participants will receive macupatide SC and eloralintide SC

    Drug: Macupatide · Drug: Eloralintide

  • Experimental
    Eloralintide Dose 3

    Participants will receive eloralintide SC

    Drug: Eloralintide

  • Experimental
    Macupatide Dose 2 + Eloralintide Dose 3

    Participants will receive macupatide SC and eloralintide SC

    Drug: Macupatide · Drug: Eloralintide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC

    Drug: Placebo

Interventions

  • DrugMacupatide

    Administered SC

    Also known as: LY3532226

  • DrugEloralintide

    Administered SC

    Also known as: LY3841136

  • DrugPlacebo

    Administered SC

05

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 48

  2. Change from Baseline in Body Weight

    Time frame: Baseline, Week 36

  3. Percentage of Participants who Achieve ≥5% Body Weight Reduction

    Time frame: Week 36

  4. Percentage of Participants who Achieve ≥10% Body Weight Reduction

    Time frame: Week 36

  5. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 36

06

Study locations

40 of 40 sites recruiting
  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
    Chandler, Arizona 85225, United States
    • Yessica Sachdeva · Principal investigator
    Recruiting
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
    • Benjamin Clark · Principal investigator
    Recruiting
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson
    Tucson, Arizona 85712, United States
    • Anita Kohli · Principal investigator
    Recruiting
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
    • Linda Gaudiani · Principal investigator
    Recruiting
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
    • Stanley Hsia · Principal investigator
    Recruiting
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
    • LeighAnn Schmidt · Principal investigator
    Recruiting
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
    • Mark Christiansen · Principal investigator
    Recruiting
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
    • David Radin · Principal investigator
    Recruiting
  • New Horizon Research Center
    Miami, Florida 33165, United States
    • Lazaro Nunez · Principal investigator
    Recruiting
  • Indago Research & Health Center, Inc
    Miami Lakes, Florida 33016, United States
    • Jose Cardona · Principal investigator
    Recruiting
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
    • Cathy Barnes · Principal investigator
    Recruiting
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
    • Edgardo Rivera-Rivera · Principal investigator
    Recruiting
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
    • Jeffrey Norton · Principal investigator
    Recruiting
  • Medical Research Partners
    Ammon, Idaho 83406, United States
    • Joseph Moore · Principal investigator
    Recruiting
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
    • Rupal Trivedi · Principal investigator
    Recruiting
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
    • susan brian · Principal investigator
    Recruiting
  • Monroe Biomedical Research - Louisville
    Louisville, Kentucky 40213, United States
    • Harold Bays · Principal investigator
    Recruiting
  • Knownwell
    Needham, Massachusetts 02492, United States
    • Angela Fitch · Principal investigator
    Recruiting
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
    • David Shih · Principal investigator
    Recruiting
  • Headlands Research - Detroit
    Southfield, Michigan 48034, United States
    • Christopher Romero · Principal investigator
    Recruiting
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
    • Neil Fraser · Principal investigator
    Recruiting
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
    • Timothy Smith · Principal investigator
    Recruiting
  • Clinvest Headlands Llc
    Springfield, Missouri 65807, United States
    • Christina Capps · Principal investigator
    Recruiting
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
    • Cornell Calinescu · Principal investigator
    Recruiting
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
    • Laszlo Mechtler · Principal investigator
    Recruiting
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
    • Patrick Connors · Principal investigator
    Recruiting
  • Medication Management
    Greensboro, North Carolina 27401, United States
    • James Franklin · Principal investigator
    Recruiting
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
    • Awawu Igbinadolor · Principal investigator
    Recruiting
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
    • Kathryn Lucas · Principal investigator
    Recruiting
  • Lucas Research, Inc.
    New Bern, North Carolina 28562, United States
    • Joseph Maides · Principal investigator
    Recruiting
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
    • James Maynard · Principal investigator
    Recruiting
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
    • Ronald Mayfield · Principal investigator
    Recruiting
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
    • Saras Sharma · Principal investigator
    Recruiting
  • IMA Clinical Research Austin
    Austin, Texas 78745, United States
    • Nomita Kim · Principal investigator
    Recruiting
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
    • Michael Downing · Principal investigator
    Recruiting
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
    • Amer Al-Karadsheh · Principal investigator
    Recruiting
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
    • Nitendra Agarwal · Principal investigator
    Recruiting
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
    • Eduardo Luna · Principal investigator
    Recruiting
  • Sovah Clinical Research-River District
    Danville, Virginia 24541, United States
    • Stephan Jannach · Principal investigator
    Recruiting
  • Central Washington Health Services Association d/b/a Confluence Health
    Wenatchee, Washington 98801, United States
    • Kathryn Eren · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Sap, Csr

08

Registry details

Key details

Study ID
NCT07589608
Lead sponsor
Eli Lilly and Company
Responsible party
Sponsor
First posted
May 15, 2026
Start date
May 15, 2026
Primary completion
Sep 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 22, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Overweight→

Other studies from this sponsor

Eli Lilly and Company

Start the discussion